<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Colorectal Cancer on XU LAB</title>
    <link>http://cmaorx.github.io/en/tags/colorectal-cancer/</link>
    <description>Recent content in Colorectal Cancer on XU LAB</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Sat, 11 Aug 2018 11:03:32 +0800</lastBuildDate>
    
	<atom:link href="http://cmaorx.github.io/en/tags/colorectal-cancer/index.xml" rel="self" type="application/rss+xml" />
    
    
    <item>
      <title>New breakthroughs</title>
      <link>http://cmaorx.github.io/en/post/post1/</link>
      <pubDate>Sat, 11 Aug 2018 11:03:32 +0800</pubDate>
      
      <guid>http://cmaorx.github.io/en/post/post1/</guid>
      <description>&lt;p&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp; &amp;nbsp;A team of Chinese, Japanese and Korean researchers led by Professor Xu Ruihua of Sun Yat-sen University&amp;rsquo;s Cancer Hospital conducted a large-scale, multi-center, phase III clinical trial of patients with advanced colorectal cancer after failed first-line treatment, AXEPT Research (Study No. NCT01996306) Objective To investigate the efficacy and tolerance of the modified double-drug combination scheme ( capecitabine+ irinotecan, XELIRI for short).&lt;/p&gt;

&lt;p&gt;&lt;/p&gt;</description>
    </item>
    
  </channel>
</rss>